×
VAXART, INC EBITDA 2010-2025 | VXRT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
VAXART, INC ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
VAXART, INC EBITDA 2010-2025 | VXRT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
VAXART, INC ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$72.3B
Zoetis (ZTS)
$68.6B
Takeda Pharmaceutical (TAK)
$47.6B
Daiichi Sankyo, - (DSNKY)
$46.4B
BeOne Medicines - (ONC)
$32.7B
Sandoz Group AG (SDZNY)
$27.7B
Summit Therapeutics (SMMT)
$18.1B
Merck (MKKGY)
$16.3B
Shionogi (SGIOY)
$14.8B
United Therapeutics (UTHR)
$13.9B
Neurocrine Biosciences (NBIX)
$13.8B
IPSEN (IPSEY)
$11.6B
Orion OYJ (ORINY)
$11.2B
Madrigal Pharmaceuticals (MDGL)
$9.7B
Eisai (ESAIY)
$9.1B
Corcept Therapeutics (CORT)
$7.3B
Stevanato Group S.p.A (STVN)
$7.1B
Ionis Pharmaceuticals (IONS)
$6.8B
Grifols, S.A (GRFS)
$6.8B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
Hypermarcas (HYPMY)
$2.8B
Procaps Group, S.A (PROCF)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$2.2B